XXXX in @entity2033 .

@entity1 @entity146 @entity4790 @entity203 @entity2033 @entity1037
OBJECTIVES: To study the effect of @entity1037 (OL) in @entity2033 ( @entity2033 ) @entity1 . DESIGN AND METHODS: Eleven @entity2033 @entity1 (five @entity1 ), aged 47.6 +/- 11.4 years and with disease duration of 11.2 +/- 3.3 years received OL. Assessment was carried out using the Clinical Global Impression of Change Scale (CGIC) and the Unified @entity2033 Rating Scale behavioral (UHDRS - b) and motor (UHDRS - m) at 6 month intervals. RESULTS: Nine @entity1 were treated for 9.8 +/- 5.9 months. The mean OL dose/ @entity1 was 11.4 +/- 8.5 mg/day (median 10 mg/day). Mean CGIC was 2.1 +/- 0.8. UHDRS - b improved significantly (P < 0.0001) and UHDRS - m did not change. @entity4790 improved in five @entity1 and two dropped out because of @entity203 and lack of efficacy. CONCLUSION: OL is a good alternative treatment in @entity2033 , mainly for the @entity146 symptoms and moderately effective for the motor symptoms, possibly because of its effect on @entity4790 . We suggest OL should be used in @entity2033 @entity1 with the adult onset form, severe @entity4790 and/or severe @entity146 disturbances.
